Analyst Scoreboard: 7 Ratings For Tandem Diabetes Care
Portfolio Pulse from Benzinga Insights
Analysts have varied ratings for Tandem Diabetes Care (NASDAQ:TNDM), with a mix of bullish and indifferent sentiments. The average 12-month price target has increased to $50.57. Tandem Diabetes Care has shown revenue growth but faces challenges with negative net margins and returns on equity and assets.
September 23, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Tandem Diabetes Care has received mixed analyst ratings, with a new average price target of $50.57. The company shows revenue growth but struggles with negative net margins and returns on equity and assets.
The mixed analyst ratings and increased price target suggest a neutral short-term impact on TNDM's stock price. While revenue growth is a positive indicator, the negative net margins and returns on equity and assets highlight ongoing financial challenges, balancing the overall outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100